e03015f06f
- Source: inbox/queue/2025-12-12-utmb-uthealth-texas-ibogaine-impact-50m-oud.md - Domain: health - Claims: 2, Entities: 1 - Enrichments: 2 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
3 KiB
| type | entity_type | name | full_name | domain | status | founded | headquarters | website | tags | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| entity | research_program | Texas IMPACT Consortium | Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma | health | active | 2025-12 | Texas, USA | null |
|
Overview
The Texas IMPACT (Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma) Consortium represents the largest state-sponsored psychedelic research investment in US history, with $50 million from Texas Health and Human Services Commission plus up to $50 million ARPA-H federal match for a potential $100 million total.
Structure
Lead institutions: UTHealth Houston and UTMB Health (Galveston)
Consortium members (11 institutions):
- UTHealth Houston
- UTMB Health
- Texas Tech University
- Texas Tech UTHS El Paso
- UT Austin
- UT Health Science Center San Antonio
- UT Tyler
- UT Rio Grande Valley
- Texas A&M University
- University of North Texas Health Science Center
- Baylor College of Medicine
- JPS Health Network (Dallas)
Research Design
Duration: Two-year multicenter trial (Phase 2 scale)
Conditions targeted:
- Opioid use disorder (primary indication) — UTHealth Houston + UTMB
- Traumatic brain injury — UT Austin + Baylor College of Medicine
- PTSD — coordinated across sites
Key evidence basis:
- Stanford 2024 study (n=30 veterans): 88% PTSD reduction, 87% depression reduction at 1 month
- MAPS Phase 2 OUD: 70-75% abstinence at 1 month
- Mechanism: Opioid receptor reset + GDNF production → dopaminergic neuron regeneration
- Unique capability: Abolishes opioid withdrawal symptoms within 1-2 days
Regulatory Context
Current status: Ibogaine is Schedule I (federal) with no completed Phase 3 trial in US
Safety barrier: QT prolongation risk with >30 documented deaths in unsupervised settings
Political support:
- Texas SB 2308 (December 2025): Authorized $50M state funding
- Trump EO (April 2026): Directed ARPA-H funding toward ibogaine for veterans; DEA to initiate rescheduling upon Phase 3 completion
- Colorado Proposition 122: Decriminalized in Colorado
Timeline
- 2025-12 — Texas SB 2308 authorizes $50M state funding for IMPACT consortium
- 2026-04 — Trump executive order directs ARPA-H to provide up to $50M federal match and commits DEA to rescheduling process upon Phase 3 completion
Significance
The Texas IMPACT consortium addresses the opioid overdose crisis (79,384 deaths in 2024), the most acute public health emergency in mental health/substance use. Ibogaine is the only psychedelic with credible single-session evidence for OUD specifically. The program demonstrates bipartisan political support through veteran-focused framing, with conservative Texas authorizing the largest state psychedelic research investment in US history.
Realistic FDA approval timeline: 2029-2030 if Phase 2 data supports Phase 3 advancement, making ibogaine 4-5 years behind psilocybin despite addressing higher-mortality condition.